PMID- 23726578
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the 
      B-cell complement-dependent lymphocytotoxicity cross-match.
PG  - 1383-5
LID - S0041-1345(13)00070-5 [pii]
LID - 10.1016/j.transproceed.2013.01.039 [doi]
AB  - BACKGROUND: The AbCross enzyme-linked immunosorbent assay (ELISA) cross-match is 
      a recently introduced solid phase cross-match technique with several technical 
      advantages over the currently available Antibody Monitoring System ELISA 
      cross-match. METHODS: In the present study, we investigated the potential 
      superiority of AbCross over the traditional complement-dependent 
      lymphocytotoxicity (CDC) B-cell cross-match (BXM). Pretransplant sera of 271 
      kidney transplant recipients who were transplanted at our center between 1998 and 
      2010 were tested in ELISA screening for the presence of human leukocyte antigen 
      (HLA) antibodies and in AbCross and CDC for antibody reactivity against 
      solubilized donor HLA class I and II antigens and donor B cells, respectively. 
      RESULTS: Patients positive for HLA class I or II antibodies on ELISA screening 
      had a significantly poorer graft outcome 2 years after transplantation than 
      recipients who were negative for HLA antibodies (21% vs 6% graft loss; P = .002). 
      Corresponding with this finding, 37 recipients positive for HLA antibodies in 
      AbCross against donor HLA class I or II antigens had a 2-year post-transplant 
      graft loss rate of 19%, which is significantly higher than the 8% rate in 186 
      recipients who were negative for both antibody classes in AbCross (P = .043). The 
      2-year graft loss rate in 34 AbCross positive but BXM negative patients was 21%, 
      compared with 7% in 172 AbCross and BXM negative patients (P = .012) and 9% in 11 
      AbCross negative but BXM positive patients (P = .39). CONCLUSIONS: Our data 
      indicate that the AbCross ELISA cross-match is superior to the CDC BXM, most 
      likely because it detects antibodies against donor HLA antigens at a higher 
      sensitivity.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Gombos, P
AU  - Gombos P
AD  - Department of Transplantation Immunology, University of Heidelberg, Heidelberg, 
      Germany. petra.gombos@med.uni-heidelberg.de
FAU - Opelz, G
AU  - Opelz G
FAU - Scherer, S
AU  - Scherer S
FAU - Morath, C
AU  - Morath C
FAU - Zeier, M
AU  - Zeier M
FAU - Schemmer, P
AU  - Schemmer P
FAU - Langer, R M
AU  - Langer RM
FAU - Susal, C
AU  - Susal C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Antibodies/*immunology
MH  - B-Lymphocytes/*immunology
MH  - Complement System Proteins/*immunology
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Kidney Transplantation
EDAT- 2013/06/04 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/14 00:00 [received]
PHST- 2013/01/15 00:00 [accepted]
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - S0041-1345(13)00070-5 [pii]
AID - 10.1016/j.transproceed.2013.01.039 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1383-5. doi: 10.1016/j.transproceed.2013.01.039.